{"id":1017575,"date":"2026-11-05T09:35:52","date_gmt":"2026-11-05T14:35:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/"},"modified":"2026-11-05T09:35:52","modified_gmt":"2026-11-05T14:35:52","slug":"precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/","title":{"rendered":"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants<\/b><\/p>\n<p>DURHAM, N.C.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nPrecision BioSciences, Inc. (Nasdaq: DTIL) (\u201cPrecision\u201d), a clinical stage gene editing company utilizing its novel proprietary ARCUS<sup>\u00ae<\/sup> platform to develop <i>in vivo<\/i> gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock at a price of $7.749995 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the $0.000005 per share exercise price for each pre-funded warrant. The gross proceeds to Precision from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $125 million. The deal includes participation from new and existing investors, including First Light Asset Management, MPM BioImpact, Bleichroeder LP, Lynx1 Capital Management, Readout Capital, Aberdeen Investments, Driehaus Capital Management, as well as other leading life sciences investors.<\/p>\n<p>\nThe offering is expected to close on or about November 6, 2026, subject to customary closing conditions. All shares of common stock and pre-funded warrants to be sold in the offering will be sold by Precision. Precision intends to use the net proceeds of the offering to fund the continued research and development of PBGENE-HBV and PBGENE-DMD, and for working capital and general corporate purposes.<\/p>\n<p>\nTD Cowen and Guggenheim Securities are acting as joint book-running managers for the offering.<\/p>\n<p>\nThe securities described above were offered by means of a prospectus supplement dated November 5, 2026, and accompanying prospectus dated January 7, 2026, forming part of Precision\u2019s effective shelf registration statement (File No. 333-292478). The prospectus supplement and accompanying prospectus relating to this offering will be filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) and will be available on the SEC\u2019s website located at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54635895&amp;newsitemid=20261104579338&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=1&amp;md5=bad62abf19dc3507f0ee6240a95394d2\"><i>www.sec.gov<\/i><\/a>. Copies of the prospectus supplement and the accompanying prospectus may also be obtained, when available, by contacting: TD Securities (USA) LLC, c\/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at <a rel=\"nofollow\" href=\"mailto:TDManualrequest@broadridge.com\">TDManualrequest@broadridge.com<\/a>; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8<sup>th<\/sup> Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at <a rel=\"nofollow\" href=\"mailto:GSEquityProspectusDelivery@guggenheimpartners.com\">GSEquityProspectusDelivery@guggenheimpartners.com<\/a>.<\/p>\n<p>\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities in this offering in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n<p><b>About Precision BioSciences, Inc.<\/b><\/p>\n<p>\nPrecision is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS<sup>\u00ae<\/sup> genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, Precision\u2019s pipeline is comprised of <i>in vivo<\/i> gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nCertain statements contained in this press release, including those relating to the timing and size of the offering, the anticipated total gross proceeds from the offering and other statements relating to the offering, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the proposed offering, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the offering, the completion of the offering on the anticipated terms or at all, general economic conditions and other risks identified from time to time in the reports Precision files with the SEC, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and the prospectus supplement and accompanying prospectus related to the proposed offering to be filed with the SEC, which are or will be available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54635895&amp;newsitemid=20261104579338&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=3752edc6a40f5555ffe77d4abae761a0\"><i>www.sec.gov<\/i><\/a>. The forward-looking statements in this press release speak only as of the date of this document, and Precision undertakes no obligation to update or revise any of the statements. Precision\u2019s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104579338r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261104579338\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261104579338\/en\/<\/a><\/span><\/p>\n<p><b>Investor and Media Contact:<br \/>\n<\/b><br \/>Naresh Tanna<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Naresh.tanna@precisionbiosciences.com\">Naresh.tanna@precisionbiosciences.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America North Carolina<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> FDA Other Health Technology Nanotechnology Stem Cells Pharmaceutical General Health Infectious Diseases Genetics Fitness &amp; Nutrition Clinical Trials Biotechnology Science Other Science Research Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261104579338\/en\/593587\/3\/Precision_BioSciences_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants DURHAM, N.C.&#8211;(BUSINESS WIRE)&#8211; Precision BioSciences, Inc. (Nasdaq: DTIL) (\u201cPrecision\u201d), a clinical stage gene editing company utilizing its novel proprietary ARCUS\u00ae platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock at a price of $7.749995 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the $0.000005 per share exercise price for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017575","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants DURHAM, N.C.&#8211;(BUSINESS WIRE)&#8211; Precision BioSciences, Inc. (Nasdaq: DTIL) (\u201cPrecision\u201d), a clinical stage gene editing company utilizing its novel proprietary ARCUS\u00ae platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock at a price of $7.749995 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the $0.000005 per share exercise price for &hellip; Continue reading &quot;Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T14:35:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104579338r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants\",\"datePublished\":\"2026-11-05T14:35:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/\"},\"wordCount\":845,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104579338r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/\",\"name\":\"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104579338r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-05T14:35:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104579338r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104579338r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/","og_locale":"en_US","og_type":"article","og_title":"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk","og_description":"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants DURHAM, N.C.&#8211;(BUSINESS WIRE)&#8211; Precision BioSciences, Inc. (Nasdaq: DTIL) (\u201cPrecision\u201d), a clinical stage gene editing company utilizing its novel proprietary ARCUS\u00ae platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock at a price of $7.749995 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the $0.000005 per share exercise price for &hellip; Continue reading \"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T14:35:52+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104579338r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","datePublished":"2026-11-05T14:35:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/"},"wordCount":845,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104579338r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/","name":"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104579338r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-05T14:35:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104579338r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104579338r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-announces-pricing-of-125-million-underwritten-offering-of-common-stock-and-pre-funded-warrants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017575"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017575\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}